Eur J Vasc Endovasc Surg:毛细管扩张丛生与过敏症和出血倾向相关

2018-02-12 AlexYang MedSci原创

最近,有研究人员调查了毛细管扩张丛生(TM)病理并且还鉴定了相关的风险因子。研究包括了352名连续性的病人,他们经历了静脉学实践,其中25名病人患有TM(7.1%)。所有25名病人均为女性,且平均年龄为45岁(27-57岁)。研究人员进行了综合的医疗历史分析。在评估的27个可能的风险因素中,具有统计学显著相关性的包括复发性鼻出血,容易挫伤,过敏症(湿疹、荨麻疹、花粉热、鼻炎),下肢静脉之前的硬化疗

最近,有研究人员调查了毛细管扩张丛生(TM)病理并且还鉴定了相关的风险因子。

研究包括了352名连续性的病人,他们经历了静脉学实践,其中25名病人患有TM(7.1%)。所有25名病人均为女性,且平均年龄为45岁(27-57岁)。研究人员进行了综合的医疗历史分析。在评估的27个可能的风险因素中,具有统计学显著相关性的包括复发性鼻出血,容易挫伤,过敏症(湿疹、荨麻疹、花粉热、鼻炎),下肢静脉之前的硬化疗法或者血管内激光治疗以及毛细血管扩张家族历史。与TM不相关的变量包括避孕药的摄入量、激素取代疗法和年龄。另外,对患有TM的12名患者(6名男性,6名女性)的止血剂和凝固分析表明与那些没有TM的对照相比没有差异。

最后,研究人员指出,TM与过敏症和出血倾向相关。他们的研究阐释了与对照组相比,在患有TM的病人中,止血剂异常的发生并没有显著的增加。由于TM与过敏障碍具有显著的相关性,阐释巨细胞的超敏性也许能够更好地理解过敏症和出血倾向于TM患者之间的相关性。

原始出处:

Kadam P, Lim J, Paver I et al. Telangiectatic Matting is Associated with Hypersensitivity and a Bleeding Tendency. Eur J Vasc Endovasc Surg. 3 Feb 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938795, encodeId=ad7d1938e95d4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 05:07:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684736, encodeId=00b91684e366c, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Sat Oct 06 18:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288414, encodeId=d48d2884149f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Feb 16 14:48:03 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288392, encodeId=484f288392da, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Feb 16 11:54:37 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516450, encodeId=fe14151645049, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Feb 14 11:07:00 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-09-20 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938795, encodeId=ad7d1938e95d4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 05:07:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684736, encodeId=00b91684e366c, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Sat Oct 06 18:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288414, encodeId=d48d2884149f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Feb 16 14:48:03 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288392, encodeId=484f288392da, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Feb 16 11:54:37 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516450, encodeId=fe14151645049, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Feb 14 11:07:00 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-10-06 lsj637
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938795, encodeId=ad7d1938e95d4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 05:07:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684736, encodeId=00b91684e366c, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Sat Oct 06 18:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288414, encodeId=d48d2884149f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Feb 16 14:48:03 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288392, encodeId=484f288392da, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Feb 16 11:54:37 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516450, encodeId=fe14151645049, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Feb 14 11:07:00 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-16 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938795, encodeId=ad7d1938e95d4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 05:07:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684736, encodeId=00b91684e366c, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Sat Oct 06 18:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288414, encodeId=d48d2884149f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Feb 16 14:48:03 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288392, encodeId=484f288392da, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Feb 16 11:54:37 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516450, encodeId=fe14151645049, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Feb 14 11:07:00 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-16 神功盖世

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1938795, encodeId=ad7d1938e95d4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Sep 20 05:07:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684736, encodeId=00b91684e366c, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Sat Oct 06 18:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288414, encodeId=d48d2884149f, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Feb 16 14:48:03 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288392, encodeId=484f288392da, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Feb 16 11:54:37 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516450, encodeId=fe14151645049, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Feb 14 11:07:00 CST 2018, time=2018-02-14, status=1, ipAttribution=)]

相关资讯

Asia Pac Allergy:2016年墨尔本风暴性哮喘流行分析:哮喘、鼻炎和其他过敏症

2016年11月21日,墨尔本经历了风暴性哮喘流行。尽管在以前的文献中有所报道,风险因素和自然史仍旧没有完全阐释。最近,有研究人员跟踪调查了在流行期间,在他们的急诊室(EDs)就医的病人,并且对他们以往的哮喘、鼻炎和过敏症进行了评估。研究人员回顾了对在风暴事件48小时内的所有呼吸道表现的ED记录,并且包括了急性哮喘的病人。另外,研究人员还围绕哮喘诊断、未诊断哮喘症状和鼻炎程度设计了标准化的调查问卷

AJCN:过敏症来袭怎么办?新型益生菌组合疗法显神效

当进入过敏季节我们可能并不太会拿出手帕或者打喷嚏来预防过敏,日前,一项刊登在国际杂志The American Journal of Clinical Nutrition上的研究报告中,来自佛罗里达大学的研究人员通过研究发现,一种益生菌组合或许能够帮助减轻花粉症的症状。 很多研究都发现,益生菌能够

美研究称过敏症会加剧偏头痛发作的频率及程度

据《俄罗斯商业咨询日报》12月1日消息,美国研究人员研究发现,花粉症(季节性过敏性鼻炎)会增加偏头痛发作的频率和严重程度。 研究人员对约6000名偏头痛患者病例进行分析后发现,有三分之二的患者为花粉症受害者。专家还得出结论认为,与其他人相比,过敏症患者偏头痛发病率为33%。 据报道,该研究是第一个证实偏头痛发作频率与鼻粘膜刺激及炎症有关联的研究。有研究人员说道: